More than one-third of African American patients with monoclonal gammopathy of undetermined significance or multiple myeloma were found to have an inherited risk factor for the disease, according to the results of a European study.
More than one-third of African-American patients with monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma were found to have an inherited risk factor for the disease, according to the results of a European study.
“Since hyperphosphorylated paratarg-7 (pP-7) carrier state was shown to be the first molecularly defined autosomal-dominantly inherited risk factor for MGUS and multiple myeloma in a European population, the prevalence of pP-7 carrier state among African Americans who have a significantly higher incidence of MGUS/multiple myeloma is of interest,” wrote Michael Pfreundschuh, MD, of Saarland University Medical School in Homburg, Germany, and colleagues.
According to Pfreundschuh, because more than one-third of paraproteins in African-American patients with MGUS/multiple myeloma recognize pP-7 as an autoantigenic target, “this post-translationally modified autoantigen is the probable autoantigenic stimulus for the development of MGUS/multiple myeloma in these patients.”
Using isoelectric focusing and ELISA, Pfreundschuh and colleagues tested the prevalence of a pP-7 carrier state and the incidence of P-7–specific paraproteins in African American, European, and Asian patients with MGUS/multiple myeloma and healthy controls. They published their results in the International Journal of Cancer.
Of the patients with MGUS/multiple myeloma, 37% of African Americans had a paraprotein reacting with P-7 compared with 16.7% of Europeans (P < .001) and 4% of Japanese patients (P < .001). The difference between European and Japanese patients was also statistically significant.
Results showed that the prevalence of healthy pP-7 carriers was also greater among healthy African-Americans (11%) compared with healthy Europeans (1.5%; P < .001) and healthy Japanese (0.4%; P < .001) participants.
“It is surprising that such a high percentage of MGUS/multiple myeloma [cases] are probably initiated by a single (post-translationally) modified autoantigen,” Pfreundschuh told Cancer Network. “Since the hyperphosphorylated variant of paratarg-7 is inherited in an autosomal-dominant fashion, relatives of MGUS/multiple myeloma patients, with a paratarg-7–specific paraprotein at risk for MGUS/multiple myeloma, can be identified.”
The prevalence of pP-7 carriers was lower in all ethnic groups among healthy patients than among patients with MGUS/multiple myeloma. Therefore, healthy controls had an elevated risk for the condition among African American (odds ratio [OR] = 4.8; 95% confidence interval [CI], 2.2–10.3), European (OR = 13.6; 95% CI, 6.3–29.3), and Japanese (OR = 11.5; 95% CI, 1.4–94.1) controls.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.